Osage Venture Partners
Osage Venture Partners is a venture capital firm based in Bala Cynwyd, Pennsylvania, with an additional office in Princeton, New Jersey. Founded in 1990, the firm specializes in early-stage investments, focusing primarily on business-to-business (B2B) software and technology-enabled services. Osage Venture Partners also invests in sectors such as life sciences, healthcare IT, media, telecommunications, and various software applications, including security and data analytics. The firm typically targets companies located on the East Coast and in the Mid-Atlantic region of the United States, specifically from Washington, D.C. to New York to Pittsburgh. Osage Venture Partners invests between $1 million and $4 million in companies with annual revenues ranging from $500,000 to $3 million, aiming to support determined entrepreneurs in building high-growth businesses. The firm actively participates in governance by leading or co-leading investment rounds and engaging on the boards of its portfolio companies.
Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases. The company's technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomal dysfunction or aberrant activation of the innate immune system.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.
Coho Therapeutics is a biotechnology company that develops molecular glue therapeutics. The company was founded in 2019 by Bruce Clurman and Jayson Punwani and is headquartered in San Diego, California, United States.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases. Nido Bio is developing solutions for severe neurological illnesses based on today's advances in neuroscience. The company creates precise medications using human genetics that treat the underlying biology of disease and restore healthy cell function.
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed specifically for the treatment of acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing for selective targeting of the cancer without harming normal cells. This innovative approach seeks to minimize the toxicities associated with traditional immunotherapies, which often affect both cancerous and healthy tissues. By protecting healthy stem cells from depletion while generating functional immune cells, Vor Biopharma aims to enhance therapeutic outcomes for patients with hematological malignancies.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
LunaPBC is a developer of a community-owned genomic and medical research platform intended for health research projects with non-profits and for-profits to drive medical discoveries. The company is a Public Benefit Corporation that enables people to share their health data for medical research for the greater good of the community. Its members also get to share the earnings that come from medical breakthroughs through shared community ownership of the database.
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
Melior Discovery is dedicated to uncovering new therapeutic applications for partners' existing drugs. By utilizing the unique and highly efficient theraTRACEÂ indications discovery platform, Melior can systematically study a single compound in multiple in vivo models, thereby evaluating potential utility in a variety of major therapeutic areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.